| Patent Number |
Title Of Patent |
Date Issued |
| RE38253 |
Composition for contraception |
September 16, 2003 |
| A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg of ethinylestradiol;and a gestagen selected from .[.0.25 to 0.30.]. .Iadd.2.5 to 3.0 .Iaddend.mg of drospirenone and .[.0.1 to 0.2.]. .Iad |
| RE37838 |
Composition for contraception |
September 10, 2002 |
| A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from .[.0.25 to 0.30 mg of.]. drospirenone and .[.0.1 to 0.2 mg of.]. cyproterone acetate, followe |
| RE37564 |
Composition for contraception |
February 26, 2002 |
| A combination product for oral contraception is disclosed comprising an estrogen selected from2.0 to 6.0 mg of 17.beta.-estradiol and0.020 mg of ethinylestradiol;and a gestagen selected from.[.0.25 to 0.30.]. .Iadd.2.5 to 3.0 .Iaddend.mg of drospirenone and.[.0.1 to 0.2.]. .Iadd.1 to 2 .Iadden |
| 6995149 |
Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestr |
February 7, 2006 |
| The present invention relates to a female mammal contraceptive process consisting of the sequential administration for at least 28 days of (a) a gestagen in an ovulation-preventing dose for at least 28 days in combination with (b) a natural oestrogen for 5 to 10 days at the end of th |
| 5980940 |
Pharmaceutical combination preparation for hormonal contraception |
November 9, 1999 |
| The invention provides a pharmaceutical combination preparation with two hormone components in a packaging unit and intended for time-sequential oral administration, comprising a number of daily dosage units physically separate and individually removable in the packaging unit, whereby as |
| 5824667 |
Composition for contraception |
October 20, 1998 |
| A combination product for oral contraception is disclosed comprising an estrogen selected from2.0 to 6.0 mg of 17.beta.-estradiol and0.020 mg of ethinylestradiol;and a gestagen selected from0.25 to 0.30 mg of drospirenone and0.1 to 0.2 mg of cyproterone acetate,followed by 5 or 4 pill-free or su |
| 5756490 |
Pharmaceutical combination preparation for hormonal contraception |
May 26, 1998 |
| A pharmaceutical combination preparation with two hormone components that are manufactured physically separately in a packaging unit and that are intended for time-sequential oral administration, which in each case consist of a number of daily dosage units that are placed physically |
| 5583129 |
Composition for contraception |
December 10, 1996 |
| This invention relates to a method of inducing contraception comprising administering an estrogen selected from2.0 to 6.0 mg of 17.beta.-estradiol and0.015 to 0.020 mg of ethinylestradiol;and a gestagen selected from0.05 to 0.075 mg of gestodene,0.075 to 0.125 mg of levonorgestrel,0.06 to 0.15 m |
| 4794119 |
Aqueous crystalline suspension of steroid glycoesters |
December 27, 1988 |
| An aqueous crystalline suspension of a 17-tertiary steroid glycoester contains a compound of Formula I ##STR1## wherein X is two hydrogen atoms or an oxygen atom,Y is two hydrogen atoms or a methylene group,R.sup.1 is hydrogen or methyl,Z is hydroxy or --O--CO--R.sup.2R.sup.2 is methyl o |
